← ANALYST RATINGS · TIPRANKS
Prime Medicine, Inc. (PRME): analyst forecast and price target
Price targets and ratings of
Analyst consensus
Strong Buy7 Buy1 Hold0 Sell
Ratings of 8 analysts in the last 3 months12-month forecast
$7.67+120.9% upside
Based on 8 price targets given in the last 3 months, the average target is $7.67, the highest $11.00, the lowest $5.00. The average is +120.9% from the last price of $3.47.
Highest target $11.00
Average target $7.67
Lowest target $5.00
Analyst ratings 13
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.00 → $3.50+16.7% | Hold | +0.9% | Reiterated | 17.10.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.00 → $3.50+16.7% | Hold | +0.9% | Reiterated | 17.10.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.00 → $3.50+16.7% | Hold | +0.9% | Reiterated | 17.10.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.00 → $3.50+16.7% | Hold | +0.9% | Reiterated | 17.10.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.00 → $3.50+16.7% | Hold | +0.9% | Reiterated | 17.10.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.00 → $3.50+16.7% | Hold | +0.9% | Reiterated | 17.10.26on TipRanks 06:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 → $3.00−14.3% | Hold | −13.5% | Reiterated | 15.10.26on TipRanks 07:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 → $3.00−14.3% | Hold | −13.5% | Reiterated | 15.10.26on TipRanks 07:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 → $3.00−14.3% | Hold | −13.5% | Reiterated | 15.10.26on TipRanks 07:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 → $3.00−14.3% | Hold | −13.5% | Reiterated | 15.10.26on TipRanks 07:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.50 → $3.00−14.3% | Hold | −13.5% | Reiterated | 15.10.26on TipRanks 07:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 → $3.00−14.3% | Hold | −13.5% | Reiterated | 15.10.26on TipRanks 07:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.00 → $3.50−12.5% | Hold | +0.9% | Reiterated | 09.10.26on TipRanks 02:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.00 → $3.50−12.5% | Hold | +0.9% | Reiterated | 09.10.26on TipRanks 02:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.00 → $3.50−12.5% | Hold | +0.9% | Reiterated | 09.10.26on TipRanks 02:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.00 → $3.50−12.5% | Hold | +0.9% | Reiterated | 09.10.26on TipRanks 02:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.00 → $3.50−12.5% | Hold | +0.9% | Reiterated | 09.10.26on TipRanks 02:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 → $3.50−12.5% | Hold | +0.9% | Reiterated | 09.10.26on TipRanks 02:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 → $4.00+14.3% | Hold | +15.3% | Reiterated | 08.10.26on TipRanks 10:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 → $4.00+14.3% | Hold | +15.3% | Reiterated | 08.10.26on TipRanks 10:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 → $4.00+14.3% | Hold | +15.3% | Reiterated | 08.10.26on TipRanks 10:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 → $4.00+14.3% | Hold | +15.3% | Reiterated | 08.10.26on TipRanks 10:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.50 → $4.00+14.3% | Hold | +15.3% | Reiterated | 08.10.26on TipRanks 10:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 → $4.00+14.3% | Hold | +15.3% | Reiterated | 08.10.26on TipRanks 10:06 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.00 → $3.50+16.7% | Hold | +0.9% | Reiterated | 07.10.26on TipRanks 07:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.00 → $3.50+16.7% | Hold | +0.9% | Reiterated | 07.10.26on TipRanks 07:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.00 → $3.50+16.7% | Hold | +0.9% | Reiterated | 07.10.26on TipRanks 07:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.00 → $3.50+16.7% | Hold | +0.9% | Reiterated | 07.10.26on TipRanks 07:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.00 → $3.50+16.7% | Hold | +0.9% | Reiterated | 07.10.26on TipRanks 07:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.00 → $3.50+16.7% | Hold | +0.9% | Reiterated | 07.10.26on TipRanks 07:05 | — | |
| Cory Jubinville, PhD★★★★★★★★★★#618 · hits 54% · avg +27.1% | LifeSci Capital | $6.00 | Buy | +72.9% | Reiterated | 05.10.26on TipRanks 16:05 | +8.5%next day +11.7% · 5 days −5.0% | ↗ |
| Arthur He CFA★★★★★★★★★★#323 · hits 58% · avg +36.5% | H.C. Wainwright | $8.00 | Buy | +130.5% | Reiterated | 01.10.26on TipRanks 10:25 | −2.3%next day −1.1% · 5 days +18.4% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.00 | Hold | −13.5% | Reiterated | 29.09.26on TipRanks 08:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.00 | Hold | −13.5% | Reiterated | 29.09.26on TipRanks 08:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.00 | Hold | −13.5% | Reiterated | 29.09.26on TipRanks 08:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.00 | Hold | −13.5% | Reiterated | 29.09.26on TipRanks 08:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.00 | Hold | −13.5% | Reiterated | 29.09.26on TipRanks 08:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.00 | Hold | −13.5% | Upgrade | 29.09.26on TipRanks 08:06 | — | |
| Kostas Biliouris★★★★★★★★★★#9060 · hits 41% · avg −0.1% | Oppenheimer | $11.00 | Buy | +217.0% | Reiterated | 25.09.26on TipRanks 09:15 | −6.1%next day −0.1% · 5 days +3.0% | ↗ |
| David Lebowitz★★★★★★★★★★#597 · hits 60% · avg +14.2% | Citi | $9.00 | Buy | +159.4% | Reiterated | 24.09.26on TipRanks Sep 25 09:15 | −1.8%next day −6.1% · 5 days −2.2% | ↗ |
| Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% | TD Cowen | — | Buy | — | Reiterated | 24.09.26on TipRanks Sep 25 04:10 | −1.8%next day −6.1% · 5 days −2.2% | ↗ |
| Keay Nakae★★★★★★★★★★#3914 · hits 40% · avg +3.0% | Chardan Capital | $7.00 | Buy | +101.7% | Reiterated | 24.09.26on TipRanks 23:30 | −6.1%next day −0.1% · 5 days +3.0% | ↗ |
| Cory Jubinville, PhD★★★★★★★★★★#618 · hits 54% · avg +27.1% | LifeSci Capital | $6.00 | Buy | +72.9% | Reiterated | 24.09.26on TipRanks 17:45 | −6.1%next day −0.1% · 5 days +3.0% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | — | Hold | — | Assigned | 10.08.26on TipRanks 09:00 | +2.3%next day +3.8% · 5 days +0.7% | ↗ |
| Arthur He CFA★★★★★★★★★★#323 · hits 58% · avg +36.5% | H.C. Wainwright | $8.00 | Buy | +130.5% | Reiterated | 10.08.26on TipRanks 06:16 | +2.3%next day +3.8% · 5 days +0.7% | ↗ |
| Boris Peaker★★★★★★★★★★#357 · hits 49% · avg +22.6% | JonesTrading | $5.00 | Buy | +44.1% | Reiterated | 06.08.26on TipRanks 19:55 | +3.8%next day +2.3% · 5 days −0.1% | ↗ |
| Unknown Analyst | Wedbush | $8.00 | Buy | +130.5% | Reiterated | 22.06.26on TipRanks Jun 27 05:07 | +4.6%next day −2.4% · 5 days +10.8% | ↗ |
| Tessa Romero★★★★★★★★★★#805 · hits 57% · avg +21.7% | J.P. Morgan | — | Hold | — | Reiterated | 18.11.25on TipRanks 18:15 | +4.4%next day +0.7% · 5 days −2.8% | ↗ |
| Samantha Semenkow★★★★★★★★★★#6889 · hits 47% · avg +0.7% | Citi | $5.00 → $4.25−15.0% | Hold | +22.5% | Reiterated | 11.11.25on TipRanks 06:45 | +11.1%next day −9.5% · 5 days −6.1% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Prime Medicine, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
3 months
Cory Jubinville, PhD★★★★★★★★★★LifeSci Capital · #618
Hits 54%71 of 131
Average return +27.1%
2 years
Cory Jubinville, PhD★★★★★★★★★★LifeSci Capital · #618
Hits 54%71 of 131
Average return +27.1%
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $7.67 at a price of $3.06 (+151.0%); now: $7.67 at $3.47 (+120.9%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 10 | 13 | 14 | 14 | 12 |
| Buy | 5 | 2 | 2 | 1 | 2 | 1 |
| Hold | 3 | 3 | 4 | 3 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 30.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.24 (from $-0.28 to $-0.19). Last quarter: $-0.24.
Sales
Next quarter’s sales estimate — $1M (from $0M to $3M). Last quarter: $1M.
Best top-analyst consensus in the sector · Healthcare
About Prime Medicine, Inc.
- CEO: Allan Reine
- Employees: 146
- 60 First Street, Cambridge, MA, 02141, US
- www.primemedicine.com
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
Data from the stock’s TipRanks forecast page, read 81 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗